@article{oai:ompu.repo.nii.ac.jp:00000321,
 author = {MORIMOTO, Takako and HIRAO, Mayumi and SANO, Hiroyuki and TERASAKI, Jungo and HANAFUSA, Toshiaki and IMAGAWA, Akihisa},
 issue = {1-2},
 journal = {Bulletin of Osaka Medical and Pharmaceutical University},
 month = {Dec},
 note = {Type 1 diabetes (T1D) is characterized by immune-related pancreatic β-cell destruction. The CD300e antibody level transiently increases during the acute phase of fulminant T1D (FT1D). Here, we investigated the contribution of CD300e to T1D development. Monocytes were obtained from 20 patients with FT1D, 25 with acute onset T1D (AT1D), 14 with type 2 diabetes (T2D), and 17 healthy controls (HCs). Additionally, peripheral blood mononuclear cells (PBMCs) were obtained from 8 patients with FT1D, 12 with AT1D, 11 with T2D, and 9 HCs. Using flow cytometry, we analyzed CD300e expression in monocytes and myeloid dendritic cells in PBMCs. Tumor necrosis factor (TNF)-α was measured after the stimulation of monocytes with 3.3 ng/µL sphingomyelin (SM), a CD300e ligand. The percentage of CD300e-positive cells in the monocytes of patients with AT1D was higher than that in those of HCs (p = 0.006). 
The percentage of CD300e-positive cells was higher in female participants than in male participants, and was negatively correlated with the estimated glomerular filtration rate and age (sex p = 0.023, eGFR p = 0.028, age p = 0.023). 
There was no difference in SM-stimulated TNF-α production by monocytes among diabetic subtypes. We showed differences in CD300e expression in human monocytes with diabetes type, sex, age, and renal function. These results provide information on the physiological features of CD300e and insights into the role of CD300e in AT1D pathogenesis.},
 pages = {29--37},
 title = {High Monocyte CD300e Expression in Patients with  Acute Onset Type 1 Diabetes},
 volume = {68},
 year = {2022}
}